These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 1923504)
1. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Casey G; Lo-Hsueh M; Lopez ME; Vogelstein B; Stanbridge EJ Oncogene; 1991 Oct; 6(10):1791-7. PubMed ID: 1923504 [TBL] [Abstract][Full Text] [Related]
2. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297 [TBL] [Abstract][Full Text] [Related]
3. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. Liang Y; Wu J; Stancel GM; Hyder SM J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260 [TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Isaacs WB; Carter BS; Ewing CM Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816 [TBL] [Abstract][Full Text] [Related]
5. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Chen YM; Chen PL; Arnaiz N; Goodrich D; Lee WH Oncogene; 1991 Oct; 6(10):1799-805. PubMed ID: 1923505 [TBL] [Abstract][Full Text] [Related]
6. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785 [TBL] [Abstract][Full Text] [Related]
7. Distinct promoter usage of mdm2 gene in human breast cancer. Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627 [TBL] [Abstract][Full Text] [Related]
8. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Li H; Weinstein IB Cancer Res; 2006 Dec; 66(23):11399-408. PubMed ID: 17145886 [TBL] [Abstract][Full Text] [Related]
9. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cajot JF; Anderson MJ; Lehman TA; Shapiro H; Briggs AA; Stanbridge EJ Cancer Res; 1992 Dec; 52(24):6956-60. PubMed ID: 1458487 [TBL] [Abstract][Full Text] [Related]
10. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line]. Wang H; Lai B; Li J Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947 [TBL] [Abstract][Full Text] [Related]
11. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774 [TBL] [Abstract][Full Text] [Related]
12. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Kang H; Mansel RE; Jiang WG Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059 [TBL] [Abstract][Full Text] [Related]
14. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
15. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312 [TBL] [Abstract][Full Text] [Related]
16. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Vinyals A; Peinado MA; Gonzalez-Garrigues M; Monzó M; Bonfil RD; Fabra A Gene Ther; 1999 Jan; 6(1):22-33. PubMed ID: 10341872 [TBL] [Abstract][Full Text] [Related]
17. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833 [TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Wang NP; To H; Lee WH; Lee EY Oncogene; 1993 Feb; 8(2):279-88. PubMed ID: 8426737 [TBL] [Abstract][Full Text] [Related]
19. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Ogretmen B; Safa AR Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]